Efficacy of pharmacological and interventional treatment for resistant hypertension-a network meta-analysis.

Management of resistant hypertension is a multifaceted approach. Selection of adequate antihypertensive treatment must consider comorbidity, risk profiles, character and preference of patients. In most circumstances, aldosterone antagonism is an important therapeutic option that might even gain more importance with the new drugs on the horizon. Further head-to-head studies are necessary to determine whether new developing pharmacological treatments offer greater efficacy in blood pressure reduction with a better safety profile than spironolactone. Long-term follow up could provide more insights into efficacy of renal denervation versus aldosterone antagonists in reducing major cardiovascular events in the real-life setting.